A changing treatment landscape for multiple sclerosis: challenges and opportunities

被引：47
作者：
Piehl, F. [1 ]
机构：
[1] Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden
来源：
JOURNAL OF INTERNAL MEDICINE | 2014年 / 275卷 / 04期
关键词：
multiple sclerosis; immunomodulatory therapy; biological therapies; randomized controlled trial; PLACEBO-CONTROLLED TRIAL; FUMARIC-ACID ESTERS; MEMORY T-CELLS; DOUBLE-BLIND; NATALIZUMAB TREATMENT; CONTROLLED PHASE-3; INTERFERON-BETA; DISEASE-ACTIVITY; BREAKTHROUGH DISEASE; GLATIRAMER ACETATE;
D O I：
10.1111/joim.12204
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Multiple sclerosis (MS) is primarily an autoimmune disease of the central nervous system, but also encompasses prominent neurodegenerative aspects. A significant proportion of MS patients will develop neurological disability over time and up until recently treatment options have been limited. However, MS treatment is now at a stage of rapid progress, with several new drugs that have reached the market or will be launched in the near future. This provides new opportunities for individualized treatment, but also creates new challenges regarding monitoring of disease activity, long-term safety issues and efficacy, not least in patients with progressive disease.
引用
收藏
页码：364 / 381
页数：18
相关论文
共 89 条
  • [31] Rituximab in Patients with Primary Progressive Multiple Sclerosis Results of a Randomized Double-Blind Placebo-Controlled Multicenter Trial
    Hawker, Kathleen
    O'Connor, Paul
    Freedman, Mark S.
    Calabresi, Peter A.
    Antel, Jack
    Simon, Jack
    Hauser, Stephen
    Waubant, Emmanuelle
    Vollmer, Timothy
    Panitch, Hillel
    Zhang, Jiameng
    Chin, Peter
    Smith, Craig H.
    [J]. ANNALS OF NEUROLOGY, 2009, 66 (04) : 460 - 471
  • [32] Smoking and two human leukocyte antigen genes interact to increase the risk for multiple sclerosis
    Hedstrom, Anna Karin
    Sundqvist, Emilie
    Baarnhielm, Maria
    Nordin, Nina
    Hillert, Jan
    Kockum, Ingrid
    Olsson, Tomas
    Alfredsson, Lars
    [J]. BRAIN, 2011, 134 : 653 - 664
  • [33] Breakthrough disease during interferon-β therapy in MS No signs of impaired biologic response
    Hesse, D.
    Krakauer, M.
    Lund, H.
    Sondergaard, H. B.
    Langkilde, A.
    Ryder, L. P.
    Sorensen, P. S.
    Sellebjerg, F.
    [J]. NEUROLOGY, 2010, 74 (18) : 1455 - 1462
  • [34] A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis
    Holmen, Carolina
    Piehl, Fredrik
    Hillert, Jan
    Fogdell-Hahn, Anna
    Lundkvist, Malin
    Karlberg, Elin
    Nilsson, Petra
    Dahle, Charlotte
    Feltelius, Nils
    Svenningsson, Anders
    Lycke, Jan
    Olsson, Tomas
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2011, 17 (06) : 708 - 719
  • [35] The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL
    Hutchinson, Michael
    Kappos, Ludwig
    Calabresi, Peter A.
    Confavreux, Christian
    Giovannoni, Gavin
    Galetta, Steven L.
    Havrdova, Eva
    Lublin, Fred D.
    Miller, David H.
    O'Connor, Paul W.
    Phillips, J. Theodore
    Polman, Chris H.
    Radue, Ernst-Wilhelm
    Rudick, Richard A.
    Stuart, William H.
    Wajgt, Andrzej
    Weinstock-Guttman, Bianca
    Wynn, Daniel R.
    Lynn, Frances
    Panzara, Michael A.
    [J]. JOURNAL OF NEUROLOGY, 2009, 256 (03) : 405 - 415
  • [36] Antibody-independent B cell effector functions in relapsing remitting Multiple Sclerosis: Clues to increased inflammatory and reduced regulatory B cell capacity
    Ireland, Sara J.
    Blazek, Monica
    Harp, Christopher T.
    Greenberg, Benjamin
    Frohman, Elliot M.
    Davis, Laurie S.
    Monson, Nancy L.
    [J]. AUTOIMMUNITY, 2012, 45 (05) : 400 - 414
  • [37] Fingolimod-associated macular edema Incidence, detection, and management
    Jain, Nieraj
    Bhatti, M. Tariq
    [J]. NEUROLOGY, 2012, 78 (09) : 672 - 680
  • [38] Johnson KP, 2012, EXPERT REV NEUROTHER, V12, P371, DOI [10.1586/ern.12.25, 10.1586/ERN.12.25]
  • [39] Modulation of dendritic cell properties by laquinimod as a mechanism for modulating multiple sclerosis
    Jolivel, Valerie
    Luessi, Felix
    Masri, Joumana
    Kraus, Stefan H. P.
    Hubo, Mario
    Poisa-Beiro, Laura
    Klebow, Sabrina
    Paterka, Magdalena
    Yogev, Nir
    Tumani, Hayrettin
    Furlan, Roberto
    Siffrin, Volker
    Jonuleit, Helmut
    Zipp, Frauke
    Waisman, Ari
    [J]. BRAIN, 2013, 136 : 1048 - 1066
  • [40] IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H)
    Jones, Joanne L.
    Phuah, Chia-Ling
    Cox, Amanda L.
    Thompson, Sara A.
    Ban, Maria
    Shawcross, Jacqueline
    Walton, Amie
    Sawcer, Stephen J.
    Compston, Alastair
    Coles, Alasdair J.
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2009, 119 (07) : 2052 - 2061
123456789